Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 20 of 20 matching drugs for HTR3C — including drugs targeting any of its 5 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
melphalan, bcnu, vitamin b12b, vitamin c, ethanol, autologous hematopoietic stem cells HTR3C Direct 2
ethanol, enoxaparin HTR3C Direct 1
amisulpride HTR3C Direct yes 0
clothiapine HTR3C Direct yes 0
dexfenfluramine HTR3C Direct yes 0
dexfenfluramine hydrochloride HTR3C Direct yes 0
tropisetron HTR3C Direct yes 0
zimeldine HTR3C Direct yes 0
zimeldine hydrochloride HTR3C Direct yes 0
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab DNMT1 SSL via DNMT1 1
decitabine, gemcitabine DNMT1 SSL via DNMT1 1
e. coli cd-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium, pharmacological study, laboratory biomarker analysis DNMT1 SSL via DNMT1 1
flucytosine, polymerase chain reaction, immunohistochemistry staining method, gene therapy, pharmacological study, 3-tesla magnetic resonance imaging, laboratory biomarker analysis, therapeutic conventional surgery, e. coli cd-expressing genetically modified neural stem cells DNMT1 SSL via DNMT1 1
ft-2102, azacitidine, nivolumab, gemcitabine and cisplatin DNMT1 SSL via DNMT1 1
pembrolizumab, azacitidine DNMT1 SSL via DNMT1 1
romidepsin, azacitidine, nab-paclitaxel, gemcitabine, durvalumab, lenalidomide capsule DNMT1 SSL via DNMT1 1
sx-682, decitabine DNMT1 SSL via DNMT1 1
tetrahydrouridine, decitabine DNMT1 SSL via DNMT1 1
azacitidine DNMT1 SSL via DNMT1 yes 0
decitabine DNMT1 SSL via DNMT1 yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.